12 Jan, 2018

Pre-Analytical Assessment of Circulating Cell-Free DNA Prepared by An Isolation-Free Enrichment Technology

Publication: ACTA Scientific Cancer Biology Volume 2 Issue 1 January 2018 Abstract Quantity and quality of circulating cell-free DNA (cfDNA) from plasma is highly variable, with frequent contamination of larger, genomic DNA as a consequence [...]

11 Jan, 2018

2018 Research Confirms CIRCULOGENE’s Clean Technology

Circulogene's Chief Scientific Officer, Dr. Chen-Hsiung Yeh, authored the latest research findings in ACTA Scientific Cancer Biology, Volume 2, Issue 1. This is the first paper released in 2018, which has important findings that include: Confirming, [...]

3 Jan, 2018

CIRCULOGENE Announces International Licensing of Proprietary Molecular Diagnostics Testing Technology to Turkey-Based Laboratory

CIRCULOGENE Announces International Licensing of Proprietary Molecular Diagnostics Testing Technology to Turkey-Based Laboratory Company expands single-blood-tube, cancer-targeted therapy and immunotherapy testing to parts of Europe, Africa, the Middle East and Commonwealth of Independent States (CIS) [...]

29 Nov, 2017

CIRCULOGENE Appoints Dr. Glen J. Weiss as Chief Medical Officer

BIRMINGHAM, Ala. ­­­– CIRCULOGENE, advancing precision medicine through personalized molecular genetics testing, has named medical oncologist and cancer researcher Glen J. Weiss, M.D., MBA, as Chief Medical Officer. Dr. Weiss will oversee and advance the [...]

17 Nov, 2017

CIRCULOGENE Featured in Genetic Engineering & Biotechnology News

November 15, 2017 Circulogene's Chen-Hsiung Yeh, Ph.D., CSO, was recently featured in a new article titled, Cell-Free DNA Drives Liquid Biopsy Testing published by Genetic Engineering & Biotechnology News. "Chen-Hsiung Yeh, Ph.D., CSO, Circulogene Theranostics, believes that what makes [...]

15 Nov, 2017

CIRCULOGENE Introduces Single-Tube, Blood-Based Microsatellite Instability (MSI) Biomarker Testing for Multiple Cancers

MSI Diagnostic Testing Available for Precision Cancer Immunotherapy BIRMINGHAM, Ala.--(BUSINESS WIRE)-- CIRCULOGENE, a leading liquid biopsy company advancing precision medicine through personalized molecular genetics testing, has announced the availability of microsatellite instability (MSI) biomarker testing for [...]

31 Oct, 2017

Key Player for Global Liquid Biopsy market

Market Research Future published a research report on "Global Liquid Biopsy Market Research Report- Forecast to 2022" and named Circulogene as one of the top key players for the global liquid biopsy market. Read more: http://www.digitaljournal.com/pr/3540438#ixzz4x60f7KoO [...]

23 May, 2017

CIRCULOGENE Expands Liquid Biopsy Testing Capabilities, Adds Three cfRNA-based NSCLC Tests Supporting Personalized Treatment for Lung Cancer Patients

Circulogene Expands Liquid Biopsy Testing Capabilities, Adds Three cfRNA-based NSCLC Tests Supporting Personalized Treatment for Lung Cancer Patients Droplet-volume, single-tube testing capabilities include both cfDNA- and cfRNA-based tests using NGS and real-time PCR platforms for [...]

27 Feb, 2017

IJRDO-Journal of Biological Science

Sample preparation of circulating cell-free DNA by direct-on-specimen and silica-based methods Andrew Ford, Charmaine Brown, Chen-Hsiung Yeh*  Circulogene Theranostics, Birmingham, USA *Corresponding author  Chen-Hsiung Yeh, PhD Circulogene Theranostics 3125 Independence Dr., Suite 301 Birmingham, AL [...]

12 Jan, 2017

Analysis of Clinical Cancer Gene Panels in Recurrent Ovarian Cancer Patients

The Next Generation Sequencing for this study was performed by Circulogene. The methodology uses cfDNA to utilize a 50 gene panel which offers the opportunity to identify genetic alterations that can be utilized to direct therapy. [...]